The use of eculizumab in gemcitabine induced thrombotic microangiopathy

The use of eculizumab in gemcitabine induced thrombotic microangiopathy

Abstract Background Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with adenocarcinomas, most notably pancreatic...

Full description

Bibliographic Details
Main Authors: Vinod Krishnappa, Mohit Gupta, Haikoo Shah, Abhijit Das, Natthavat Tanphaichitr, Robert Novak, Rupesh Raina
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Nephrology
Subjects:
Hemolytic uremic syndrome
Gemcitabine
Thrombotic microangiopathy
Renal failure
Pancreatic cancer
Online Access:http://link.springer.com/article/10.1186/s12882-018-0812-x

Internet

http://link.springer.com/article/10.1186/s12882-018-0812-x

Similar Items